A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis.

Trial Profile

A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2013

At a glance

  • Drugs Ceralifimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms DreaMS
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 23 Mar 2013 Results using the more sensitive statistical method presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 07 Dec 2012 Last checked against ClinicalTrials.gov record (Parent Trial; NCT01081782).
    • 13 Oct 2012 Results presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top